Drug Patents owned by Glaxosmithkline

1. List of Advil Allergy Sinus drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7863287 GLAXOSMITHKLINE Compositions of non-steroidal anti-inflammatory drugs, decongestants and anti-histamines
Feb, 2027

(4 years from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2002

Treatment: NA

Dosage: TABLET;ORAL

More Information on Dosage

2. List of Advil Pm drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8883849 GLAXOSMITHKLINE Treatment of sleep disturbances
Jan, 2022

(1 year, 19 days ago)

US9155718 GLAXOSMITHKLINE Treatment of sleep disturbances
Jan, 2022

(1 year, 19 days ago)

Drugs and Companies using DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN ingredient

Market Authorisation Date: 21 December, 2005

Treatment: A method of treating a patient suffering from a pain associated sleep disturbance comprising administering a liquid composition formulated inside a soft gel capsule, as claimed, to the patient

Dosage: CAPSULE;ORAL

How can I launch a generic of ADVIL PM before it's patent expiration?
More Information on Dosage

3. List of Advil Pm drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8263647 GLAXOSMITHKLINE Treatment of sleep disturbances
May, 2022

(8 months ago)

Drugs and Companies using DIPHENHYDRAMINE CITRATE; IBUPROFEN ingredient

Market Authorisation Date: 21 December, 2005

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of ADVIL PM before it's patent expiration?
More Information on Dosage

4. List of Anoro Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44874 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(a month from now)

US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(2 years from now)

US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7776895 GLAXOSMITHKLINE Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Sep, 2022

(4 months ago)

US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Jul, 2025

(2 years from now)

US8511304 GLAXOSMITHKLINE Medicament dispenser
Jun, 2027

(4 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser
Feb, 2028

(5 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(7 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(7 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
M Jun 9, 2022

Drugs and Companies using UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 December, 2013

Treatment: Indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema.; Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: POWDER;INHALATION

More Information on Dosage

5. List of Arnuity Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser
Feb, 2028

(5 years from now)

US8201556 GLAXOSMITHKLINE Medicament dispenser
Feb, 2029

(6 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(7 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(7 years from now)

Drugs and Companies using FLUTICASONE FUROATE ingredient

Market Authorisation Date: 20 August, 2014

Treatment: NA

Dosage: POWDER;INHALATION

More Information on Dosage

6. List of Children's Advil drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition
May, 2024

(1 year, 3 months from now)

Drugs and Companies using IBUPROFEN ingredient

Market Authorisation Date: 27 June, 1996

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

7. List of Children's Advil Allergy Sinus drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10238640 GLAXOSMITHKLINE Pharmaceutical suspension composition
May, 2024

(1 year, 3 months from now)

Drugs and Companies using CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient

Market Authorisation Date: 24 February, 2004

Treatment: NA

Dosage: SUSPENSION;ORAL

More Information on Dosage

8. List of Nicorette drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8323683 GLAXOSMITHKLINE Flavoring of drug-containing chewing gums
Apr, 2028

(5 years from now)

US8940772 GLAXOSMITHKLINE Nicotine lozenge composition
Apr, 2029

(6 years from now)

US8501164 GLAXOSMITHKLINE Nicotine lozenge compositions
Jun, 2029

(6 years from now)

Drugs and Companies using NICOTINE POLACRILEX ingredient

Market Authorisation Date: 09 February, 1996

Treatment: NA

Dosage: GUM, CHEWING;BUCCAL

How can I launch a generic of NICORETTE before it's patent expiration?
More Information on Dosage

9. List of Trelegy Ellipta drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44874 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
Mar, 2023

(a month from now)

US7498440 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US7439393 GLAXOSMITHKLINE Phenethanolamine derivatives for treatment of respiratory diseases
May, 2025

(2 years from now)

US7488827 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Dec, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7776895 GLAXOSMITHKLINE Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Sep, 2022

(4 months ago)

US8309572 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Apr, 2025

(2 years from now)

US8183257 GLAXOSMITHKLINE Muscarinic acetylcholine receptor antagonists
Jul, 2025

(2 years from now)

US8511304 GLAXOSMITHKLINE Medicament dispenser
Jun, 2027

(4 years from now)

US9333310 GLAXOSMITHKLINE Medicament dispenser
Oct, 2027

(4 years from now)

US8113199 GLAXOSMITHKLINE Counter for use with a medicament dispenser
Oct, 2027

(4 years from now)

US8161968 GLAXOSMITHKLINE Medicament dispenser
Feb, 2028

(5 years from now)

US8534281 GLAXOSMITHKLINE Manifold for use in medicament dispenser
Mar, 2030

(7 years from now)

US8746242 GLAXOSMITHKLINE Medicament dispenser
Oct, 2030

(7 years from now)

US11090294 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

US9750726 GLAXOSMITHKLINE Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
Nov, 2030

(7 years from now)

Exclusivity Exclusivity Expiration
New Strength (NS) Sep 9, 2023
New Indication (I) Sep 9, 2023

Drugs and Companies using FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE ingredient

Market Authorisation Date: 18 September, 2017

Treatment: Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via topical application; Method of inhibiting the binding of acetylcholine to an acetylcholine receptor in the respiratory tract of a human, comprising contacting the receptor with an effective amount of umeclidinium, via inhalation; Method of dispensing a combination medicament product from claimed delivery device, for example for the treatment of asthma or copd; Maintenance treatment of chronic obstructive pulmonary disease (copd) comprising the once per day administration of trelegy ellipta, 100 mcg fluticasone furoate/62.5 mcg umeclidinium/25 mcg vilanterol; Indicated for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (copd), including chronic bronchitis and/or emphysema; And asthma; Maintenance treatment of asthma in patients 18 yrs and older, or chronic obstructive pulmonary disease (copd) including chronic bronchitis and/or emphysema

Dosage: POWDER;INHALATION

More Information on Dosage

10. List of Ventolin Hfa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7832351 GLAXOSMITHKLINE Actuation indicator for a dispensing device
Jun, 2023

(4 months from now)

US7832351

(Pediatric)

GLAXOSMITHKLINE Actuation indicator for a dispensing device
Dec, 2023

(10 months from now)

US7500444 GLAXOSMITHKLINE Actuation indicator for a dispensing device
Feb, 2026

(3 years from now)

US7500444

(Pediatric)

GLAXOSMITHKLINE Actuation indicator for a dispensing device
Aug, 2026

(3 years from now)

Drugs and Companies using ALBUTEROL SULFATE ingredient

Market Authorisation Date: 19 April, 2001

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

11. List of Zejula drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8436185 GLAXOSMITHKLINE Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide
Apr, 2029

(6 years from now)

US8071623 GLAXOSMITHKLINE Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors
Mar, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071579 GLAXOSMITHKLINE DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(4 years from now)

US8143241 GLAXOSMITHKLINE DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(4 years from now)

US8859562 GLAXOSMITHKLINE Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(8 years from now)

US11091459 GLAXOSMITHKLINE Niraparib compositions
Mar, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 29, 2027
New Chemical Entity Exclusivity (NCE) Mar 27, 2022
New Indication (I) Apr 29, 2023

Drugs and Companies using NIRAPARIB TOSYLATE ingredient

NCE-1 date: March, 2021

Market Authorisation Date: 27 March, 2017

Treatment: A method of treatment of advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination deficiency (hrd) positive status

Dosage: CAPSULE;ORAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic